Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Adagene (ADAG)
NASDAQ:ADAG
Holding ADAG?
Track your performance easily
ADAG Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.35 - $4.38
Previous Close$2.27
Volume5.80K
Average Volume (3M)63.41K
Market Cap
$97.84M
Enterprise Value$12.69M
Total Cash (Recent Filing)$109.93M
Total Debt (Recent Filing)$22.13M
Price to Earnings (P/E)―
Beta1.05
Next Earnings
Mar 27, 2025EPS Estimate
-$0.47Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.73
Shares Outstanding44,116,671
10 Day Avg. Volume79,738
30 Day Avg. Volume63,407
Standard Deviation0.23
R-Squared0.01
Alpha-0.03
Financial Highlights & Ratios
Price to Book (P/B)1.31
Price to Sales (P/S)5.41
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit0.70
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$4.25Price Target Upside92.31% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Adagene News
PremiumCompany Announcements
Adagene Unveils Promising Data for Cancer Therapy
PremiumCompany Announcements
Adagene’s ADG126 Shows Promise in MSS CRC TherapyPremiumCompany Announcements
Adagene’s Promising Mid-Year Financials and ADG126 Update
PremiumCompany Announcements
Adagene Inc. Strikes Deal to Sell Depositary SharesPremiumCompany Announcements
Adagene’s Breakthroughs Promise Future Growth
Bulls Say, Bears Say
Bulls Say
Clinical Study ResultsADG126 in combination with pembrolizumab achieved an overall response rate (ORR) of 22% and a disease control rate (DCR) of 100% in nine evaluable patients without liver and peritoneal metastases (NLPM).
Market ValuationThe ESMO update reinforces confidence in the ADG126’s potential in NLPM MSS-CRC, and the stock is believed to be undervalued at the current market cap.
Safety ProfileThe safety profile of ADG126 is differentiated, likely due to ADAG's proprietary SAFEbody technology, which allows antibodies to be selectively activated.
Bears Say
Development DelaysThe launch timeline of ADG126 has been pushed out from 2028 to 2029, reflecting uncertainty in its development plan.
Market PerformanceADAG declined 33.2% compared to NBI index's drop of 0.3% in the last two trading days, which is believed to be unwarranted and creates an attractive entry point for long-term investors.
Regulatory ChallengesThere is little clarity on the regulatory development path for ADG126 given the selective patient population.
---
Ownership Overview
―
Insiders
0.02% Mutual Funds
13.49% Other Institutional Investors
86.49% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
ADAG FAQ
What was Adagene’s price range in the past 12 months?
Adagene lowest stock price was $1.35 and its highest was $4.38 in the past 12 months.
What is Adagene’s market cap?
Currently, no data Available
When is Adagene’s upcoming earnings report date?
Adagene’s upcoming earnings report date is Mar 27, 2025 which is in 120 days.
How were Adagene’s earnings last quarter?
Adagene released its earnings results on Jul 25, 2024. The company reported -$0.285 earnings per share for the quarter, beating the consensus estimate of -$0.41 by $0.125.
Is Adagene overvalued?
According to Wall Street analysts Adagene’s price is currently Undervalued.
Does Adagene pay dividends?
Adagene does not currently pay dividends.
What is Adagene’s EPS estimate?
Adagene’s EPS estimate is -$0.47.
How many shares outstanding does Adagene have?
Adagene has 44,156,982 shares outstanding.
What happened to Adagene’s price movement after its last earnings report?
Adagene reported an EPS of -$0.285 in its last earnings report, beating expectations of -$0.41. Following the earnings report the stock price went down -0.395%.
Which hedge fund is a major shareholder of Adagene?
Currently, no hedge funds are holding shares in ADAG
---
Adagene Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$4.25 (92.31% Upside)
$4.25 (92.31% Upside)
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
57.63%
12-Months-Change
Fundamentals
Return on Equity
-46.16%
Trailing 12-Months
Asset Growth
-25.52%
Trailing 12-Months
Company Description
Adagene
Adagene Inc is a clinical-stage immunotherapy company focused on the design and discovery of antibodies for the treatment of cancer.
---
ADAG Stock 12 Month Forecast
Average Price Target
$4.25
▲(92.31% Upside)
Technical Analysis
Best Analysts Covering ADAG
1 Year
1 Year Success Rate
7/11 ratings generated profit
1 Year Average Return
+27.95%
reiterated a buy rating 2 months ago
Copying Arthur He CFA's trades and holding each position for 1 Year would result in 63.64% of your transactions generating a profit, with an average return of +27.95% per trade.
---